Monocyte chemoattractant protein-1 -2518 A/G single nucleotide polymorphism in Chinese Han patients with ocular Behcet's disease.

Authors: Hou, S  Yang, P  Du, L  Jiang, Z  Mao, L  Shu, Q  Zhou, H  Kijlstra, A 
Citation: Hou S, etal., Hum Immunol. 2010 Jan;71(1):79-82. doi: 10.1016/j.humimm.2009.09.354. Epub .
Pubmed: (View Article at PubMed) PMID:19782713
DOI: Full-text: DOI:10.1016/j.humimm.2009.09.354

Recent studies in Caucasian uveitis patients have shown an association with the -2518 A/G polymorphism of the monocyte chemoattractant protein (MCP)-1 gene. It is unknown whether this polymorphism is also associated with ocular Behcet's disease (BD) in Chinese populations. The aim of the current study was therefore to investigate the possible involvement of MCP-1 in the susceptibility to ocular BD in Chinese Han individuals. A case control association study was performed in 296 ocular BD patients and 319 geographically and age-matched healthy controls using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). Binary logistic regression analysis revealed a decreased frequency of the homozygous AA genotype and an increased frequency of AG genotype of the MCP-1 -2518 polymorphism in ocular BD patients compared with healthy controls, when adjusted for gender (p = 0.048, p = 0.028, respectively). However, when segregated on the basis of several clinical findings, no any association was found between this polymorphism and ocular BD. In conclusion, the present study suggests that the MCP-1 -2518 AA genotype seems to display a protective association with ocular BD, whereas the -2518 AG genotype might be a susceptible factor for ocular BD in the Chinese Han population.


Disease Annotations
Phenotype Annotations
Objects Annotated
Objects referenced in this article

Additional Information

CRRD Object Information
CRRD ID: 8548882
Created: 2014-03-25
Species: All species
Last Modified: 2014-03-25
Status: ACTIVE


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.